LA

Leila Alland

Dr. Alland is a biotech advisor working with entrepreneurs and investors to advance innovative diagnostic and therapeutic products for oncology and rare diseases. Previously, she has served as CMO of PMV Pharma (Nasdaq: PMVP), an oncology company, and prior to that, as CMO of Affimed (Nasdaq: AFMD), an immuno-oncology company, and as CMO of Tarveda Therapeutics, a targeted drug conjugate company. Her career includes leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RAD
RAD
30/06/251,071,740N/A10,400,002N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RAD
RAD
16/12/24
Issued
8,000,000$0.027$216,000Issue of options
RAD
RAD
13/09/24
Issued
1,000,000$0.040$40,000Placement
RAD
RAD
13/09/24
Issued
500,000$0.030$15,000Placement
RAD
RAD
08/12/23
Issued
71,740$0.070$5,021Rights issue
RAD
RAD
05/12/22
Issued
1,900,002$0.115$218,500Issue of options